Share
CNBC
Johnson & Johnson’s one-dose coronavirus vaccine is safe and appears to generate a promising immune response in both young and elderly volunteers, according to trial data published Wednesday in the New England Journal of Medicine.
J&J scientists randomly assigned healthy adults between the ages of 18 and 55 and those 65 and older to receive a high or low dose of its vaccine — called Ad26.COV2.S — or a placebo. Some participants in the 18-to-55 age group were also selected to receive a second dose of the vaccine.
Most of the volunteers produced detectable neutralizing antibodies, which researchers believe play an important role in defending cells against the virus, after 28 days, according to the trial data. By day 57, all volunteers had detectable antibodies, regardless of vaccine dose or age group, and remained stable for at least 71 days in the 18-to-55 age group.
By Berkeley Lovelace Jr. | 13 Jan 2021
RELATED TOPICS:
After Years of Undrinkable Water, Our Rural California Community Finally Has Hope
10 hours ago
Musk Calls Trump’s Big Beautiful Bill ‘a Disgusting Abomination’
10 hours ago
US Tariffs Could Put Air Safety at Risk, Aerospace and Airline Industries Warn
11 hours ago
Trump to Sign Order Doubling Metals Tariffs, White House Says
11 hours ago
Millions Invested in Land for Innovation Village. Will It Be a Fresno Game-Changer?
11 hours ago

Hegseth Orders the Name of Gay Rights Activist Harvey Milk Scrubbed From Navy Ship

Knicks Fire Coach Tom Thibodeau After First Eastern Conference Finals Berth in 25 Years

After Years of Undrinkable Water, Our Rural California Community Finally Has Hope
